Group 1: Investment Potential - Johnson & Johnson (NYSE: JNJ) is highlighted as a highly profitable blue chip stock, with Citi raising its price target from $250 to $274 while maintaining a Buy rating [1] - Citi's research note indicates that despite recent market volatility, the fundamentals of the medical technology sector remain "healthy" [1] - Citi's top picks in the sector include iRhythm and Medtronic, suggesting a competitive landscape [1] Group 2: Product Development and Regulatory Approvals - Johnson & Johnson announced the submission of a Type II variation application to the European Medicines Agency (EMA) for TECVAYLI® to treat adult patients with relapsed/refractory multiple myeloma [2] - The submission is supported by data from the Phase 3 MajesTEC-9 trial, which evaluates teclistamab's safety and efficacy against standard care in 614 patients [3] Group 3: Company Overview - Johnson & Johnson operates through two segments: Innovative Medicine and MedTech, focusing on various therapeutic areas including oncology, infectious diseases, and cardiovascular diseases [4] - The MedTech segment encompasses a wide range of medical devices used in cardiovascular intervention, orthopedics, and surgery [4]

Core Viewpoint - The article discusses the 12 most profitable blue-chip stocks to invest in currently, emphasizing the importance of diversification and identifying opportunities amidst market volatility [1][2][3]. Market Trends and Investment Strategy - Stephen Parker from JPMorgan Private Bank highlights that geopolitical events, such as the Iran war, can cause short-term market disruptions, particularly in energy markets, but typically do not have long-lasting effects [1][2]. - He advises clients to maintain a diversified and disciplined investment approach, seek opportunities during volatility, and start building a shopping list for potential investments [2][3]. Stock Selection Methodology - The selection of the 12 blue-chip stocks was based on stock screeners and holdings of blue-chip ETFs, focusing on those with the highest trailing twelve months (TTM) net income and net income margins [5]. - The list prioritizes stocks with the highest number of hedge fund holders as of Q3 2025, utilizing data from Insider Monkey's database [5][6]. Company Highlights - **AstraZeneca PLC (NASDAQ:AZN)**: - Price target raised to 16,000 GBp from 15,500 GBp by Guggenheim, maintaining a Buy rating after positive fiscal 2025 results [8]. - The FDA has accepted a supplemental Biologics License Application for Enhertu, with a Priority Review status for treating HER2-positive breast cancer [9][10]. - AstraZeneca focuses on developing and commercializing prescription medicines, including novel immuno-oncology treatments [11]. - **Johnson & Johnson (NYSE:JNJ)**: - Citi increased the price target to $274 from $250 while maintaining a Buy rating, citing healthy sector fundamentals despite recent volatility [12]. - The company submitted a Type II variation application to the EMA for TECVAYLI® to treat relapsed/refractory multiple myeloma [13][14]. - Johnson & Johnson operates in healthcare, with segments in Innovative Medicine and MedTech, covering various therapeutic areas and medical devices [15].

Core Insights - Johnson & Johnson (NYSE: JNJ) has received FDA approval for TECVAYLI® plus DARZALEX FASPRO® for treating adults with relapsed or refractory multiple myeloma, marking a significant advancement in treatment options for this patient population [1][2] Group 1: FDA Approval and Treatment Impact - The FDA approval introduces a potential new standard of care for approximately 40% of multiple myeloma patients who experience disease relapse, offering a novel treatment approach [2] - TECVAYLI® and DARZALEX FASPRO® are designed to work synergistically to activate the immune system against myeloma cells expressing the BCMA protein [2] Group 2: Market Performance and Analyst Ratings - JPMorgan has raised its price target for Johnson & Johnson to $250 from $225, maintaining a Neutral rating, influenced by increased estimates for the drug Tremfya in inflammatory bowel disease [3] - The recent performance of Tremfya has contributed to the positive outlook for Johnson & Johnson's stock [3] Group 3: Company Overview - Johnson & Johnson operates in the healthcare sector, developing, manufacturing, and selling products through two main segments: Innovative Medicine and MedTech [4] - The MedTech segment encompasses a wide range of medical devices and products utilized in various fields, including cardiovascular intervention and orthopedics [4]

Core Insights - Johnson & Johnson announced FDA approval for TECVAYLI® plus DARZALEX FASPRO® for treating relapsed/refractory multiple myeloma, potentially establishing a new standard of care as early as the second line of treatment [1][2] - The approval is based on Phase 3 MajesTEC-3 study data, showing significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard treatments [1][2] Company Overview - Johnson & Johnson is a leader in multiple myeloma therapies, emphasizing its commitment to transforming treatment landscapes for this disease [1][2] - The company has a history of innovation in hematology, aiming to improve patient outcomes and accessibility to effective therapies [1][2] Treatment Efficacy - TECVAYLI® in combination with DARZALEX FASPRO® demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a three-year PFS rate of 83% versus 30% in the control arm [1][2] - The combination therapy showed higher rates of overall response (89% vs. 75.3%), complete response (81.8% vs. 32.1%), and minimal residual disease negativity (58.4% vs. 17.1%) at three years [1][2] Study Details - The MajesTEC-3 study is a randomized Phase 3 trial evaluating the safety and efficacy of teclistamab plus daratumumab against standard treatment options in patients with relapsed/refractory multiple myeloma [2] - The study's primary endpoint is PFS, with secondary endpoints including overall response rate, minimal residual disease negativity, and overall survival [2] Market Impact - The approval enhances treatment options for multiple myeloma patients, allowing for personalized treatment plans and potentially improving care accessibility [1][2] - Johnson & Johnson's new regimen is expected to address the critical need for effective therapies in patients experiencing multiple relapses [1][2] Future Aspirations - The company aims to continue advancing its multiple myeloma portfolio, with aspirations of ultimately curing the disease [1][2]

Core Insights - Johnson & Johnson (JNJ) is a diversified global healthcare leader with a market capitalization of nearly $497.2 billion, focusing on pharmaceuticals, medical devices, and consumer health products [1][2] Financial Performance - The company is expected to report a diluted Q4 EPS of $2.53, reflecting a 24% increase from last year's $2.04, and has exceeded EPS estimates in each of the past four quarters [3] - In Q3, JNJ reported a revenue increase of 6.8% year over year to $23.99 billion, surpassing expectations of $23.75 billion [4] - Adjusted EPS for Q3 climbed 15.7% year over year to $2.80, exceeding analyst estimates of $2.77, and full-year sales guidance has been raised to $93.7 billion [5] - Analysts project diluted EPS for fiscal 2025 to rise 8.9% year over year to $10.87, followed by a further 5.7% increase to $11.49 in fiscal 2026 [5] Stock Performance - Over the past 52 weeks, JNJ stock surged 43.7%, with year-to-date gains reaching 42.7%, significantly outperforming the S&P 500 Index, which rose 16.5% over the past year [6] - The outperformance is even more pronounced compared to the State Street Health Care Select Sector SPDR ETF, which increased by 13.7% over the past 52 weeks [6] Product Development - Johnson & Johnson recently released Phase 3 MajesTEC-3 data, highlighting the potential of TECVAYLI® combined with DARZALEX FASPRO® as an early second-line therapy for relapsed or refractory multiple myeloma [7]